An Interview With Peter S. Sever, MB BChir, PhD

statins

 

The Study

Sever PS, Poulter NR, Chang CL, et al; ASCOT Investigators. Evaluation of C-reactive protein prior to and on-treatment as a predictor of benefit from atorvastatin: observations from the Anglo-Scandinavian Cardiac Outcomes Trial. Eur Heart J. 2012;33:486-494.

About the Interviewee

Peter S. Sever, MB BChir, PhD, is Professor of Clinical Pharmacology and Therapeutics at Imperial College London; Honorary Consultant Physician at the Imperial Healthcare NHS Trust; and Co-director of the International Centre for Circulatory Health, London, United Kingdom. During the past decade, he established a major research program in the pathogenesis and treatment of cardiovascular disease. He is joint editor-in-chief of Journal of the Renin-Angiotensin-Aldosterone System and has been a member of the editorial boards of several journals, including Journal of Hypertension, Journal of Human Hypertension, and Clinical Science.
Professor Sever is past president of the British Hypertension Society (1989-1991) and past president of the European Council for Blood Pressure and Cardiovascular Research. He is also a Fellow of the European Society of Cardiology and past Chairman of the Fellowships Committee of the British Heart Foundation.
His current research interests include all aspects of cardiovascular disease, including the pathophysiology of vascular disease, the evaluation of antihypertensive drug therapy, and multiple risk factor intervention in hypertensive populations. He is also interested in the epidemiology of hypertension, with particular reference to environmental influences on blood pressure and ethnic differences. Professor Sever was co-chair, along with Björn Dahlöf, MD (Sahlgrenska University Hospital, Göteborg, Sweden), of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) executive committee.

Section 1 of 3

Next: Background to the Interview  »